ClinicalTrials.gg
CompletedNCT06673238Updated Jul 27, 2026

A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

A Phase 1 interventional study of ABBV-722 and Placebo in Healthy Volunteer, sponsored by AbbVie. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Phase 1, first-in-human study to investigate safety, tolerability, and pharmacokinetics of ABBV-722 after oral dosing in healthy adult participants.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
  • ABBV-722
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Laboratory values meet the criteria specified in the protocol.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead (ECG).
  • Part 2 only: Healthy Han Chinese and Japanese individuals between 18 and 65 years of age, inclusive at the time of Screening.

    • Participant must be first- or second-generation Han Chinese of full Chinese parentage (both parents of Han Chinese descent), residing outside of China. Participants must be in general good health and maintain a typical Chinese lifestyle, including consuming a typical Chinese diet.
    • First-generation participants will have been born in China to two parents and four grandparents, who were also born in China, and are of full Chinese descent.
    • Second-generation participants born outside of China must have two parents and four grandparents born in China and are of full Chinese descent. OR
    • Participant must be first- or second-generation Japanese of full Japanese parentage (both parents of Japanese descent), residing outside of Japan. Participants must be in general good health and maintain a typical Japanese lifestyle, including consuming a typical Japanese diet.
    • First-generation participants will have been born in Japan to two parents and four grandparents, who were also born in Japan, and are of full Japanese descent.
    • Second-generation participants born outside of Japan must have two parents and four grandparents born in Japan and are of full Japanese descent.

Exclusion criteria

Exclusion Criteria:

  • History of any illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.
  • Consumption of alcohol, grapefruit products, Seville oranges, starfruit products or quinine/tonic water within the 72-hour period prior to study drug administration.
  • Use of tobacco or nicotine-containing products within 180 days prior to the first dose of study drug.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Part 1: Group 1

    Participants will receive a single dose of either ABBV-722 Dose A or placebo.

    Drug: ABBV-722 · Drug: Placebo

  • Experimental
    Part 1: Group 2

    Participants will receive a single dose of either ABBV-722 Dose B or placebo.

    Drug: ABBV-722 · Drug: Placebo

  • Experimental
    Part 1: Group 3

    Participants will receive a single dose of either ABBV-722 Dose C or placebo.

    Drug: ABBV-722 · Drug: Placebo

  • Experimental
    Part 1: Group 4

    Participants will receive a single dose of either ABBV-722 Dose TBD or placebo.

    Drug: ABBV-722 · Drug: Placebo

  • Experimental
    Part 1: Group 5

    Participants will receive a single dose of either ABBV-722 Dose TBD or placebo.

    Drug: ABBV-722 · Drug: Placebo

  • Experimental
    Part 2: Group 6

    Participants who are Han Chinese will receive a single dose of ABBV-722 Dose D.

    Drug: ABBV-722

  • Experimental
    Part 2: Group 7

    Participants who are Japanese will receive a single dose of ABBV-722 Dose D.

    Drug: ABBV-722

  • Experimental
    Part 3: Group 8

    Participants will receive either ABBV-722 Dose E or placebo for 14 days.

    Drug: ABBV-722 · Drug: Placebo

  • Experimental
    Part 3: Group 9

    Participants will receive either ABBV-722 Dose F or placebo for 14 days.

    Drug: ABBV-722 · Drug: Placebo

  • Experimental
    Part 3: Group 10

    Participants will receive either ABBV-722 Dose A or placebo for 14 days.

    Drug: ABBV-722 · Drug: Placebo

  • Experimental
    Part 3: Group 11

    Participants will receive either ABBV-722 Dose G or placebo for 14 days.

    Drug: ABBV-722 · Drug: Placebo

  • Experimental
    Part 3: Group 12

    Participants will receive either ABBV-722 Dose TBD or placebo for 14 days.

    Drug: ABBV-722 · Drug: Placebo

Interventions

  • Oral Capsule

  • DrugPlacebo

    Oral Capsule

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events Reported During Safety Evaluations

    Safety evaluations will include AE monitoring, vital sign measurements (including orthostatic blood pressure and pulse rate), ECG variables, and clinical laboratory testing (hematology, chemistry, and urinalysis) as a measure of safety and tolerability for the entire study duration. Clinically significant abnormal changes in physical examination findings will be reported as AEs.

    Time frame: Up to Day 44

  2. Maximum Plasma Concentration (Cmax) of ABBV-722

    Cmax of ABBV-722.

    Time frame: Up to Day 21

  3. Time to Cmax (Tmax) of ABBV-722

    Tmax of ABBV-722.

    Time frame: Up to Day 21

  4. For Parts 1 and 2: Area Under the Concentration-Time Curve (AUC) from Time 0 to Time t (AUCt) of ABBV-722

    AUCt of ABBV-722.

    Time frame: Up to Day 8

  5. For Parts 1 and 2: Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf) of ABBV-722

    AUCinf of ABBV-722

    Time frame: Up to Day 8

  6. For Part 3: Observed Plasma Concentration at the End of the Dosing Interval (Ctrough) of ABBV-722

    Ctrough of ABBV-722.

    Time frame: Up to Day 21

  7. For Part 3: AUC from Time 0 to the End of Dosing Interval (AUCtau) Following the First and Last Doses of ABBV-722

    AUC from AUCtau following the first and last doses of ABBV-722.

    Time frame: Up to Day 21

  8. Terminal Phase Elimination Rate Constant (Beta) of ABBV-722

    Beta of ABBV-722.

    Time frame: Up to Day 21

  9. Terminal Phase Elimination Half-Life (t1/2) of ABBV-722

    t1/2 of ABBV-722.

    Time frame: Up to Day 21

  10. Dose Normalized Cmax

    Dose normalized Cmax.

    Time frame: Up to Day 21

  11. Dose Normalized AUCs

    Dose normalized AUCs.

    Time frame: Up to Day 21

07

Study locations

2 sites
  • Altasciences Clinical Los Angeles /ID# 280183
    Cypress, California 90630, United States
  • Acpru /Id# 270279
    Grayslake, Illinois 60030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Jun 2026, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2024
First posted
Nov 4, 2024
StartActual
Oct 29, 2024
Primary completionActual
Jun 25, 2026
CompletionActual
Jun 25, 2026
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06673238
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 4, 2024
Start date
Oct 29, 2024
Primary completion
Jun 25, 2026
Completion
Jun 25, 2026
Last update
Jul 27, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABBV-722

Start the discussion